All News Zentiva S.A.

Equities

End-of-day quote Bucharest S.E. Other stock markets 23:00:00 16/05/2024 BST			5-day change	1st Jan Change
3.26 ^RON	+0.62%		0.00%	+11.64%

04-01	Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution	CI
02-29	Zentiva S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Zentiva S A : SCD_Zentiva_Annual Report 2023-EN	04-30	PU
Biocon Limited, Through Zentiva, Receives Approval from, U.K., for its Complex Formulation Liraglutide (gSaxenda®) in 6mg/ml Solution	04-01	CI
Biocon is the first generics company to obtain approval for diabetes drug, Liraglutide, in the U.K.	03-28	AQ
Zentiva S A : Convening notice Zentiva S.A. – OGMS and EGMS_29.04.2024	03-27	PU
Zentiva S A : Memo_Substantiation note_OGMS_29.04.2024	03-27	PU
Zentiva S A : Draft Resolution_OGMS_29.04.2024	03-27	PU
Zentiva S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Zentiva S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	11-15	CI
Zentiva S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	31/08/23	CI
Zentiva S A : SCD_Zentiva_Fin report 30.06.2023-EN	31/08/23	PU
Zentiva S A : SCD_Zentiva_Fin report 31.03.2023-EN	15/05/23	PU
Zentiva S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	14/05/23	CI
STEFFEN SALTOFTE APPOINTED AS CEO OF ZENTIVA	19/04/23	AQ
Zentiva S A : Memo_Substantiation note_OGMS_27.04.2023	27/03/23	PU
Zentiva S A : Draft Resolution_OGMS_27.04.2023	27/03/23	PU
Zentiva S A : Auditor’s Report_31.12.2022	27/03/23	PU
Zentiva S A : Annual remuneration report for the management of Zentiva SA_2022	27/03/23	PU
Zentiva S A : Remuneration policy for the management of Zentiva_draft	27/03/23	PU
Zentiva S A : Memo_Substantiation note_EGMS_27.04.2023	27/03/23	PU
Zentiva S A : Draft Resolution_EGMS_27.04.2023	27/03/23	PU

No results for this search